Q1 Earnings Forecast for CATX Issued By HC Wainwright

Perspective Therapeutics, Inc. (NYSE:CATX) – Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Perspective Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.32) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Perspective Therapeutics’ FY2026 earnings at ($1.24) EPS.

Several other equities research analysts have also recently issued reports on CATX. Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price on the stock. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, May 13th. Finally, Truist Financial lowered their price target on shares of Perspective Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $12.50.

Perspective Therapeutics Stock Up 3.8%

Shares of CATX opened at $2.73 on Tuesday. Perspective Therapeutics has a 52-week low of $1.60 and a 52-week high of $16.90. The firm’s fifty day moving average is $2.25 and its two-hundred day moving average is $3.53.

Institutional Trading of Perspective Therapeutics

Several hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its position in shares of Perspective Therapeutics by 7.4% during the fourth quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company’s stock worth $163,000 after purchasing an additional 3,529 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Perspective Therapeutics by 4.5% during the fourth quarter. Rhumbline Advisers now owns 94,992 shares of the company’s stock worth $303,000 after purchasing an additional 4,075 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Perspective Therapeutics by 3.4% during the fourth quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company’s stock worth $458,000 after purchasing an additional 4,693 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Perspective Therapeutics by 24.1% during the third quarter. JPMorgan Chase & Co. now owns 24,912 shares of the company’s stock worth $333,000 after purchasing an additional 4,844 shares in the last quarter. Finally, ProShare Advisors LLC lifted its position in shares of Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock worth $49,000 after purchasing an additional 5,011 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Insider Buying and Selling at Perspective Therapeutics

In other Perspective Therapeutics news, CFO Juan Graham purchased 33,333 shares of Perspective Therapeutics stock in a transaction dated Friday, March 28th. The shares were acquired at an average price of $2.25 per share, with a total value of $74,999.25. Following the completion of the transaction, the chief financial officer now owns 35,354 shares of the company’s stock, valued at $79,546.50. This trade represents a 1,649.33% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert F. Williamson III purchased 22,192 shares of Perspective Therapeutics stock in a transaction dated Friday, March 28th. The shares were acquired at an average cost of $2.27 per share, for a total transaction of $50,375.84. Following the transaction, the director now directly owns 70,837 shares of the company’s stock, valued at approximately $160,799.99. This represents a 45.62% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 115,696 shares of company stock valued at $256,344 over the last 90 days. 3.72% of the stock is owned by insiders.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.